21st Austria weekly - Valneva EVN 26/05/2022 [pic1]Valneva: an Austrian/French specialty vaccine company today announced the successful completion of lot-to-lot Phase 3 trial its single-shot chikungunya candidate VLA1553. The final analysis included six-month follow-up data and confirmed topline results reported in December 2021. VLA1553-302 met primary endpoint demonstrating that three consecutively manufactured lots elicited equivalent immune responses measured by neutralizing antibody titer GMT ratios on Day 29 after vaccination.Valneva: performance: -3.91%EVN: Revenue recorded Austrian utility company Group